STMN2 and amyotrophic lateral sclerosis: Another ASO therapy concerns Stathmin-2 (STMN2) (NCT05633459), which acts as an important splice target of TDP-43 (TAR DNA-binding protein 43), and thus the loss of nuclear TDP-43, as observed in ALS leading to a Stathmin-2 mis-splicing.